chemomab.com (CMMB) Quarterly EPS earnings growth

Symbol and logo of brand chemomab.com (CMMB)

Chemomab Therapeutics (CMMB) maintains a high reputation in the therapy of rare fibrous pathologies due to its innovative antibodies. The quarterly EPS gap demonstrates yield dynamics, where this metric equals 24.30. Full capacity utilization of precision laboratories eliminates operational downtime in research. Growth potential is based on trials of the drug CM-101 and the interest of pharmaceutical behemoths in orphan drugs.

CMMB: Chemomab Therapeutics Ltd. Year-over-year earnings per one share growth for the last 12 months 07/04/2022 - 11/17/2026

chemomab.com (CMMB) - metric breakdowns and financial figures

- share price and expert price forecast:
Initial company analysis:Chemomab Therapeutics
Flagship merchandise of Chemomab Therapeutics

For Chemomab Therapeutics (CMMB), operating in an environment characterized by a shortage of therapies for rare fibro-inflammatory pathologies, earnings per share growth rates reflect the efficiency of monetizing high market demand. By analyzing quarterly EPS dynamics, investors track the percentage change in net income, which allows them to differentiate short-term market impulses from actual business scaling and assess capital stability.

Who Chemomab Therapeutics competes with

VRTX: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Alnylam Inc. (ALNY)|INSM (Insmed) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months UTHR (United Therapeutics Corporation)|Year-over-year net earnings per share growth for the last 12 months BMRN (BioMarin)|BBIO (BridgeBio Pharma) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth BGM (BGM Group Ltd)|COGT (Cogent Bio) - Year-over-year net earnings per share trend for the last twelve months|Xeris Biopharma - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months KROS (Keros Therapeutics)|ARCT: Quarterly EPS earnings growth|Eton Pharmaceuticals Inc (ETON) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months Kamada Corp|FULC: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Abeona Therapeutics, Inc. (ABEO)|Year-over-year net earnings per share growth for the last 12 months Mereo BioPharma Group plc MREO|Year-over-year earnings per share growth for the last twelve months Protalix BioTherapeutics PLX|Quarterly EPS earnings growth Pliant Therapeutics PLRX|appliedtherapeutics.com - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months RNTX (Rein Therapeutics, Inc.)|GELS: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Aytu BioPharma, Inc. (AYTU)|Year-over-year net earnings per share growth for the last 12 months SRXH|Year-over-year earnings per share growth for the last twelve months PLRZ|Quarterly EPS earnings growth AEZS|Year-over-year earnings per share growth for the last twelve months CYTH (Cyclo Therapeutics, Inc)|Inozyme Pharma - Year-over-year net earnings per share growth for the last 12 months|Reneo Pharmaceuticals, Inc. (RPHM) - Earnings per share growth in annualized terms for the last twelve months|COSCIENS Bio - Quarterly EPS earnings growth